Harmony Biosciences Holdings annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Harmony Biosciences Holdings Stock-Based Compensation Growth & History (HRMY)
Harmony Biosciences Holdings's stock-based compensation was $44.9M for fiscal 2025.
View full Harmony Biosciences Holdings company overviewHarmony Biosciences Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44.9M | $2.3M | +5.38% |
| 2024 | 2024-12-31 | $42.6M | $10.9M | +34.37% |
| 2023 | 2023-12-31 | $31.7M | $5.5M | +21.14% |
| 2022 | 2022-12-31 | $26.2M | $10.5M | +67.14% |
| 2021 | 2021-12-31 | $15.7M | $11.0M | +233.67% |
| 2020 | 2020-12-31 | $4.7M | −$5.2M | −52.64% |
| 2019 | 2019-12-31 | $9.9M | — | — |
Harmony Biosciences Holdings quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.3M | −$2.1M | −18.51% |
| Q1 2026 | 2026-03-31 | $10.6M | −$1.9M | −15.03% |
| Q4 2025 | 2025-12-31 | $10.0M | −$100,000 | −0.99% |
| Q3 2025 | 2025-09-30 | $11.0M | −$79,000 | −0.72% |
| Q2 2025 | 2025-06-30 | $11.5M | $367,000 | +3.31% |
| Q1 2025 | 2025-03-31 | $12.5M | $2.1M | +20.25% |
| Q4 2024 | 2024-12-31 | $10.1M | $1.2M | +13.64% |
| Q3 2024 | 2024-09-30 | $11.0M | $3.1M | +38.26% |
| Q2 2024 | 2024-06-30 | $11.1M | $3.4M | +44.98% |
| Q1 2024 | 2024-03-31 | $10.4M | $3.2M | +44.30% |
| Q4 2023 | 2023-12-31 | $8.9M | $1.6M | +22.08% |
| Q3 2023 | 2023-09-30 | $8.0M | $984,000 | +14.04% |
| Q2 2023 | 2023-06-30 | $7.6M | $370,000 | +5.08% |
| Q1 2023 | 2023-03-31 | $7.2M | $2.6M | +55.64% |
| Q4 2022 | 2022-12-31 | $7.3M | $3.1M | +72.94% |
| Q3 2022 | 2022-09-30 | $7.0M | $2.8M | +64.75% |
| Q2 2022 | 2022-06-30 | $7.3M | $3.4M | +86.28% |
| Q1 2022 | 2022-03-31 | $4.6M | $1.3M | +40.20% |
| Q4 2021 | 2021-12-31 | $4.2M | $1.4M | +48.71% |
| Q3 2021 | 2021-09-30 | $4.3M | $3.2M | +296.37% |
| Q2 2021 | 2021-06-30 | $3.9M | $3.5M | +810.72% |
| Q1 2021 | 2021-03-31 | $3.3M | $2.9M | +797.01% |
| Q4 2020 | 2020-12-31 | $2.8M | — | — |
| Q3 2020 | 2020-09-30 | $1.1M | $666,000 | +163.64% |
| Q2 2020 | 2020-06-30 | $429,000 | — | — |
| Q1 2020 | 2020-03-31 | $368,000 | — | — |
| Q3 2019 | 2019-09-30 | $407,000 | — | — |
Harmony Biosciences Holdings stock-based compensation trends
Over the last five fiscal years, Harmony Biosciences Holdings's stock-based compensation increased from $4.7M to $44.9M, a change of $40.2M. The latest reported quarter, Q2 2026, shows $9.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Harmony Biosciences Holdings source filings ↗